Dr Reddy’s Laboratories (DRL) suffered a 68% fall in Q4 net profit ended March 2008, after writing down the intangible value of the product...

Glenmark Pharmaceuticals has received final approval to market a generic version of GlaxoSmithKline’s popular anti-emetic drug Zofran, that...

Glenmark Pharmaceuticals says it has received the US Food and Drug Administration approval to market two of its cancer drugs.

: Buoyed by overseas acquisitions and new product launches in regulated markets, the pharma sector recorded exponential growth in the fourt...

Hyderabad-Based Dr Reddy’s has crossed revenues of $1.5 billion or Rs 6,500 crore in 2006-07 against Rs 2,400 crore (FY06) piggybacking on ...

Generic drug makers, which have typically waged legal battles against innovator pharma giants, are now suing each other to protect their ma...

Buoyed by overseas acquisitions and strong growth in key international markets, pharma companies could see an overall 38% increase in net p...

With anti-cancer blockbuster drugs set to go off-patent in the US in the next three to four years, generic players are gearing up to tap th...

Dr Reddy’s Laboratories has gained entry into the $1-billion club with its nine months’ revenue of 2006-07.

Dr Reddy’s Labs’ (DRL) generic version of GlaxoSmithKline’s (GSK) Zofran could generate revenues of around Rs 200 crore ($45 million) in th...

Pharmaceutical firm Dr Reddy's Laboratories Ltd has received approval from the US Food and Drug Administration to market Ondansetron Hydroc...